Stay updated with breaking news from Study Week. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Takeda Announces China NMPA Approval of LIVTENCITY maribavir for the Treatment of Adults With Posttransplant Cytomegalovirus CMV Refractory to Prior Therapies
In the December 1960 / January 1961 issue of the NICAP UFO Investigator journal, a small article was published under the
In the December 1960 / January 1961 issue of the NICAP UFO Investigator journal , a small article was published under the
If Approved, Maribavir Would be the First and Only Inhibitor of CMV-specific UL97 Protein Kinase in the EU for Treatment of Adults with Post-transplant CMV Refractory (With or Without Resistance) to
Data Include Exploratory Analysis Showing LIVTENCITY Treated Patients With Post-Transplant Cytomegalovirus (CMV) Infections/Disease Had Reductions in Hospitalizations (34.8%; p=0.021) and Length